Microencapsulation of a synthetic peptide epitope for HTLV-1 in biodegradable poly(D,L-lactide-co-glycolide) microspheres using a novel encapsulation technique
Author:
- 1 January 2001
- journal article
- Published by Taylor & Francis in Journal of Microencapsulation
- Vol. 18 (5) , 663-677
Abstract
A novel procedure has been developed for the encapsulation of peptide antigens in poly(lactide-co-glycolide) (PLGA) microspheres, which employs trifluoro-acetic acid (TFA) as a carrier solvent for both the polymer and antigen. The antigen/polymer solution is emulsified in mineral oil containing sorbitan trioleate (Span 85) as an emulsifier and a low level of cottonseed oil to extract the TFA. Fluoresceinisothiocyanate-labelled bovine serum albumin (FITC-BSA) was used as a model antigen to characterize the microencapsulation. Microspheres were of the desired size (<10 microm) for targeting to antigen-presenting cells, and released the model antigen slowly after an initial burst release (11%) in PBS/0.02% Tween 80 at 37 degrees C. Subsequently, a potential peptide vaccine, designated MVFMF2, for the human T-lymphotropic virus type 1 (HTLV-1 ) was encapsulated at 4.7% loading using the novel oil-in-oil method. In vivo immune responses were examined in rabbits immunized with (i) encapsulated MVFMF2 together with encapsulated adjuvant (N-acetyl-glucosamine-3yl-acetyl-L-alanyl-D-isoglutamine, nor-MDP, (ii) encapsulated MVFMF2 without adjuvant, and (iii) free peptide with adjuvant. Inoculation of the encapsulated peptide produced an antibody response similar to that of the free peptide emulsified in adjuvant. Moreover, the elevated immune response elicited by the encapsulated peptide was observed without multiple booster immunizations and irrespective of whether an adjuvant was used. Additionally, the antibodies raised against both free and encapsulated MVFMF2 had similar affinities, as judged by competitive enzyme-linked immunosorbant assay (ELISA), indicating that the encapsulated peptide retained a significant fraction of its epitopes. Hence, these results demonstrate that peptide vaccines can be encapsulated in PLGA microspheres using a common carrier solvent for both the peptide and polymer, which produces a desirable immune response in the absence of an adjuvant.Keywords
This publication has 20 references indexed in Scilit:
- Modulation of rifampicin release from spray-dried microspheres using combinations of poly-(DL-lactide)Journal of Microencapsulation, 1999
- Effect of formulation variables on in vitro drug release and micromeritic properties of modified release ibuprofen microspheresJournal of Microencapsulation, 1999
- Biodegradable microspheres as controlled-release tetanus toxoid delivery systemsVaccine, 1994
- Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humansJournal of General Virology, 1990
- Identification of two promiscuous T cell epitopes from tetanus toxinEuropean Journal of Immunology, 1990
- Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cellsEuropean Journal of Immunology, 1989
- Murine MHC Polymorphism and T Cell SpecificitiesScience, 1989
- A malaria T-cell epitope recognized in association with most mouse and human MHC class II moleculesNature, 1988
- Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: Influence of molecular weight and copolymer ratio of polymer.Chemical and Pharmaceutical Bulletin, 1988
- A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid.Chemical and Pharmaceutical Bulletin, 1988